Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Binder, Mascha ^a   Léchenne, Barbara ^a   Ummanni, Ramesh ^a   Scharf, Christan ^b   Balabanov, Stefan ^a   Trusch, Maria ^a   Schlüter, Hartmut ^a   Braren, Ingke ^c   Spillner, Edzard ^c   Trepel, Martin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CELL ANTIGEN; CELL EXTRACT; VIMENTIN; ANTIGEN; IMMUNOGLOBULIN G; LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ADHESION; CELL INTERACTION; CELL PROTECTION; CELL STIMULATION; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN HEAVY CHAIN GENE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STROMA CELL; CHEMISTRY; CYTOLOGY; FLUORESCENCE MICROSCOPY; GENETICS; HELA CELL; IMMUNOLOGY; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTIGENS; CALRETICULIN; COMPLEMENTARITY DETERMINING REGIONS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HELA CELLS; HUMANS; IMMUNOGLOBULIN G; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MICROSCOPY, FLUORESCENCE; RECEPTORS, ANTIGEN, B-CELL; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STROMAL CELLS; VIMENTIN;

EID: 78651227932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015992     Document Type: Article

References (57)

1. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352: 804-815.
2. Dighiero G, Hamblin TJ (2008) Chronic lymphocytic leukaemia. Lancet 371: 1017-1029.
3. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, et al. (1994) The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8: 1640-1645.
4. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, et al. (2000) Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96: 2655-2663.
5. Burger JA, Kipps TJ (2002) Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma 43: 461-466.
6. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114: 3367-3375.
7. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P (1998) Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91: 2387-2396.
8. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV (1996) Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 92: 97-103.
9. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, et al. (2002) Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 100: 1795-1801.
10. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, et al. (2009) Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113: 5549-5557.
11. Balakrishnan K, Burger JA, Wierda WG, Gandhi V (2009) AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113: 149-153.
12. Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, et al. (2005) Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 106: 1012-1020.
13. Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, et al. (2005) CD38 and CD100 lead a network of surface receptors relaying positive signals for BCLL growth and survival. Blood 105: 3042-3050.
14. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ (2001) Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest 107: 305-315.
15. Redondo-Munoz J, Ugarte-Berzal E, Garcia-Marco JA, del Cerro MH, Van den Steen PE, et al. (2008) Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 112: 169-178.
16. Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, et al. (2009) CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 69: 4001-4009.
17. Chiorazzi N, Ferrarini M (2003) B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 21: 841-894.
18. Stevenson FK, Caligaris-Cappio F (2004) Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 103: 4389-4395.
19. Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, et al. (2007) Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 109: 259-270.
20. Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, et al. (2004) Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 200: 519-525.
21. Refaeli Y, Young RM, Turner BC, Duda J, Field KA, et al. (2008) The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol 6: e152.
22. Tobin G (2005) The immunoglobulin genes and chronic lymphocytic leukemia (CLL). Ups J Med Sci 110: 97-113.
23. Stamatopoulos K, Belessi C, Hadzidimitriou A, Smilevska T, Kalagiakou E, et al. (2005) Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood 106: 3575-3583.
24. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, et al. (1998) Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102: 1515-1525.
25. Ghiotto F, Fais F, Albesiano E, Sison C, Valetto A, et al. (2006) Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia. Mol Med 12: 300-308.
26. Thorselius M, Krober A, Murray F, Thunberg U, Tobin G, et al. (2006) Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 107: 2889-2894.
27. Tobin G (2007) The immunoglobulin genes: structure and specificity in chronic lymphocytic leukemia. Leuk Lymphoma 48: 1081-1086.
28. Tobin G, Thunberg U, Johnson A, Eriksson I, Soderberg O, et al. (2003) Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 101: 4952-4957.
29. Sthoeger ZM, Wakai M, Tse DB, Vinciguerra VP, Allen SL, et al. (1989) Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 169: 255-268.
30. Dighiero G, Hart S, Lim A, Borche L, Levy R, et al. (1991) Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas. Blood 78: 581-585.
31. Chiorazzi N, Hatzi K, Albesiano E (2005) B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens. Ann N Y Acad Sci 1062: 1-12.
32. Herve M, Xu K, Ng YS, Wardemann H, Albesiano E, et al. (2005) Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 115: 1636-1643.
33. Lanemo Myhrinder A, Hellqvist E, Sidorova E, Soderberg A, Baxendale H, et al. (2008) A new perspective: molecular motifs on oxidized-LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood.
34. Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, et al. (2009) High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 113: 3050-3058.
35. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, et al. (2009) B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 114: 1029-1037.
36. Bertinetti C, Simon F, Zirlik K, Heining-Mikesch K, Pfeifer D, et al. (2006) Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli. Eur J Haematol 77: 395-402.
37. Osterroth F, Alkan O, Mackensen A, Lindemann A, Fisch P, et al. (1999) Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination. J Immunol Methods 229: 141-153.
38. Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, et al. (2008) Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 111: 1524-1533.
39. Braren I, Blank S, Seismann H, Deckers S, Ollert M, et al. (2007) Generation of human monoclonal allergen-specific IgE and IgG antibodies from synthetic antibody libraries. Clin Chem 53: 837-844.
40. Braren I, Greunke K, Umland O, Deckers S, Bredehorst R, et al. (2007) Comparative expression of different antibody formats in mammalian cells and Pichia pastoris. Biotechnol Appl Biochem 47: 205-214.
41. Ummanni R, Junker H, Zimmermann U, Venz S, Teller S, et al. (2008) Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett 266: 171-185.
42. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20: 3551-3567.
43. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, et al. (2003) The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 31: 365-370.
44. Eriksson JE, He T, Trejo-Skalli AV, Harmala-Brasken AS, Hellman J, et al. (2004) Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. J Cell Sci 117: 919-932.
45. Xu B, deWaal RM, Mor-Vaknin N, Hibbard C, Markovitz DM, et al. (2004) The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. Mol Cell Biol 24: 9198-9206.
46. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, et al. (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6: R142-150.
47. Bohn W, Wiegers W, Beuttenmuller M, Traub P (1992) Species-specific recognition patterns of monoclonal antibodies directed against vimentin. Exp Cell Res 201: 1-7.
48. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM (2003) Vimentin is secreted by activated macrophages. Nat Cell Biol 5: 59-63.
49. Chu CC, Catera R, Hatzi K, Yan XJ, Zhang L, et al. (2008) Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 112: 5122-5129.
50. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, et al. (2009) Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114: 4441-4450.
51. Buchner M, Baer C, Prinz G, Jumaa H, Veelken H, et al. (2009) Spleen Tyrosine Kinase Inhibition Prevents Chemokine- and Integrin-Mediated Stromal Protective Effects in Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 114: 2356.
52. Quiroga MP, Kurtova A, Wierda W, Keating M, Burger JA (2008) Inhibition of BCR Signaling Using the SYK Inhibitor R406 Antagonizes Migratory and Pro- Survival Responses in CLL Cells. Blood (ASH Annual Meeting Abstracts) 112: 2064.
53. Li SS, Forslow A, Sundqvist KG (2005) Autocrine regulation of T cell motility by calreticulin-thrombospondin-1 interaction. J Immunol 174: 654-661.
54. Obeid M (2008) ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin. J Immunol 181: 2533-2543.
55. Johnson S, Michalak M, Opas M, Eggleton P (2001) The ins and outs of calreticulin: from the ER lumen to the extracellular space. Trends Cell Biol 11: 122-129.
56. Verreck FA, Elferink D, Vermeulen CJ, Amons R, Breedveld F, et al. (1995) DR4Dw4/DR53 molecules contain a peptide from the autoantigen calreticulin. Tissue Antigens 45: 270-275.
57. Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, vanVenrooij WJ (2004) Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 350: 17-34.